Interview with Amit Mehta, Managing Director, S. Amit & Co
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Address: 101-A Neelam Centre, 249-B Hind Cycle Road, Worli, Mumbai 400 030, India
Tel: +91 22 4001 3000
S. Amit Speciality Chemicals Pvt. Ltd. is a leading full-service Chemistry Solutions provider in India delivering products and services in the areas of speciality chemicals, intermediates and performance chemicals for diverse applications including pharmaceuticals, agrochemicals, polymers & plastics, and paints and coating.
Over the last six decades, the Company has transitioned from representing international laboratory chemical suppliers to marketing 1 or 2 steps of chemistries to supplying advanced intermediates and performance chemicals such as reducing agents, resolving agents, encapsulated catalysts, etc. Focussed on its broad-based relationships with both customers and suppliers, the objective has always been to add value to the chemical supply chain for both parties.
Today, as an integrated solutions provider, the S. Amit Group of Companies focuses on offering a full range of supply chain services including – representation of manufacturers, global and local sourcing, distribution, virtual manufacturing, and identifying problems and recommending innovative chemical solutions. This allows our customers and suppliers to effectively extract value from the supply chain based on their needs and the market situation.
In January 2011, S. Amit acquired Reaxa U.K., a company actively involved in developing and supplying encapsulated metal catalysts for synthetic organic chemistry.
Through its various group companies, the S. Amit Group provides
Indenting
Local Sales and Distribution
Exports
Virtual Manufacturing Services
Products and services are branded through the following group companies – S. Amit, Finorga,
Chem Amit, Perfo Chem and Brom Chem
The S. Amit Group also has a joint venture company, Diamines & Chemicals Ltd. that manufactures piperazine at its plant in Baroda, Gujarat.
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Ananya Chakraborty from the Vydehi Institute of Medical Sciences & Research Centre outlines the key factors behind India’s successful…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
See our Cookie Privacy Policy Here
